Unlocking the Potential of Lenvatinib and Anti-PD-1 in Treating Unresectable Liver Cancer
The study explores the efficacy of Lenvatinib plus anti-PD-1 antibodies as a conversion therapy for patients with unresectable hepatocellular carcinoma, showing promising results and identifying pre-existing CD8(+) cells as a ...